Novo Nordisk Seeks To Halt Sanofi Insulin Pen
Novo Nordisk A/S is asking a New Jersey federal court to stop Sanofi-Aventis sales of recently launched insulin pen SoloStar....To view the full article, register now.
Already a subscriber? Click here to view full article